Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM91LGU)

Drug Name
Abexinostat Drug Info
Synonyms
PCI-24781; 783355-60-2; ABEXINOSTAT; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide
Cross-matching ID
PubChem CID
11749858
ChEBI ID
CHEMBL2103863
CAS Number
CAS 783355-60-2
TTD Drug ID
D0V0SL

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Aldosterone-regulated sodium reabsorption 2.13 0.00e+0 34/37 (91.89%) SGK1;ATP1B1;ATP1A1;...
Synaptic vesicle cycle 2.12 0.00e+0 63/78 (80.77%) SLC1A1;STXBP1;ATP6V1D;...
Carbohydrate digestion and absorption 1.95 7.37e-3 37/47 (78.72%) ATP1B1;ATP1A1;HK1;...
Lysosome 1.94 8.29e-3 115/128 (89.84%) LIPA;FUCA1;LGMN;...
Endocrine and other factor-regulated calcium reabsorpti... 1.90 6.63e-3 49/53 (92.45%) ADCY9;ATP1B1;PRKACA;...
Oxidative phosphorylation 1.87 1.29e-2 93/133 (69.92%) ATP6V1D;ATP6V1A;ATP6V0D1;...
Collecting duct acid secretion 1.78 2.53e-2 22/27 (81.48%) ATP6V1D;ATP6V1A;ATP6V0D1;...
Fructose and mannose metabolism 1.78 2.21e-2 30/33 (90.91%) ALDOC;AKR1B1;ALDOB;...
Glycerolipid metabolism 1.76 2.58e-2 44/61 (72.13%) AKR1B1;AKR1B10;LPIN1;...
Cholesterol metabolism 1.76 2.43e-2 44/50 (88%) LIPA;NPC1;NPC2;...
Steroid biosynthesis 1.76 2.21e-2 19/20 (95%) LIPA;TM7SF2;SC5D;...
mTOR signaling pathway 1.75 2.03e-2 114/154 (74.03%) SGK1;ATP6V1D;RPS6KA2;...
SNARE interactions in vesicular transport 1.74 2.04e-2 19/33 (57.58%) STX7;SNAP29;STX2;...
Sulfur metabolism 1.74 2.05e-2 9/10 (90%) PAPSS2;TST;ETHE1;...
Bacterial invasion of epithelial cells 1.74 1.92e-2 59/77 (76.62%) CAV2;CAV1;PIK3CD;...
Regulation of lipolysis in adipocytes 1.71 2.42e-2 52/55 (94.55%) GNAI2;ADCY9;PRKACA;...
Glycerophospholipid metabolism 1.70 2.60e-2 71/98 (72.45%) PLA2G15;GPD1L;CDIPT;...
Ribosome biogenesis in eukaryotes -1.69 4.48e-2 52/108 (48.15%) GTPBP4;RPP38;FCF1;...
Fanconi anemia pathway -1.69 4.83e-2 36/54 (66.67%) TOP3A;ATR;MLH1;...
RNA transport -1.74 2.82e-2 128/186 (68.82%) NCBP1;NUP155;XPO1;...
IL-17 signaling pathway -1.79 1.86e-2 84/94 (89.36%) TRAF6;HSP90AB1;MAPK10;...
DNA replication -1.81 1.89e-2 34/36 (94.44%) SSBP1;RFC1;RFC4;...
Spliceosome -2.00 0.00e+0 101/150 (67.33%) SNRPA;DHX15;HSPA6;...
One carbon pool by folate -2.02 0.00e+0 15/20 (75%) GART;MTHFD2L;DHFR;...
Pyrimidine metabolism -2.04 0.00e+0 40/56 (71.43%) NT5E;ENTPD6;UMPS;...
Cell cycle -2.05 0.00e+0 110/124 (88.71%) TGFB3;CDC20;ESPL1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H